Sep 13 |
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
|
Aug 14 |
Elicio Therapeutics GAAP EPS of -$0.64
|
Aug 13 |
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
|
Aug 12 |
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
|
Jun 28 |
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
|
Jun 18 |
Elicio Therapeutics Reports Inducement Grants
|
May 16 |
Elicio Therapeutics GAAP EPS of -$1.15
|
May 16 |
BayWa r.e. and Elicio to build 270MW floating wind farm in France
|
Apr 25 |
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
|
Apr 5 |
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
|